Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab
Tiziana Life Sciences dosed the first three participants in the Phase 2a Healey ALS MyMatch BANYAN trial of intranasal foralumab in ALS. The trial will enroll 44 individuals with early ALS in a 3:1 randomized, placebo-controlled 12-week treatment period plus a 12-week active extension, with a safety/tolerability primary endpoint and biomarker-based secondary endpoints. The study is co-funded by the ALS Association and led at the Healey & AMG Center, with additional sites at Northwestern, University of Minnesota, and Nova Southeastern.
Key figures
- Drug Name
- intranasal foralumab
- Phase Of Trial
- Phase 2a
- Participants
- 44
- Randomization
- 3:1 (active drug : placebo)
- Primary endpoint
- Safety and tolerability of foralumab in patients with ALS
- Clinicaltrials id
- NCT07688239
- Extension duration weeks
- 12
- Treatment duration weeks
- 12
- Ea na spms patients dosed
- 14
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.